16,125 research outputs found
Alterations of immune response of non-small lung cancer with azacytidine
Innovative therapies are needed for advanced Non-Small Cell Lung Cancer (NSCLC). We have undertaken a genomics based, hypothesis driving, approach to query an emerging potential that epigenetic therapy may sensitize to immune checkpoint therapy targeting PD-L1/PD-1 interaction. NSCLC cell lines were treated with the DNA hypomethylating agent azacytidine (AZA - Vidaza) and genes and pathways altered were mapped by genome-wide expression and DNA methylation analyses. AZA-induced pathways were analyzed in The Cancer Genome Atlas (TCGA) project by mapping the derived gene signatures in hundreds of lung adeno (LUAD) and squamous cell carcinoma (LUSC) samples. AZA up-regulates genes and pathways related to both innate and adaptive immunity and genes related to immune evasion in a several NSCLC lines. DNA hypermethylation and low expression of IRF7, an interferon transcription factor, tracks with this signature particularly in LUSC. In concert with these events, AZA up-regulates PD-L1 transcripts and protein, a key ligand-mediator of immune tolerance. Analysis of TCGA samples demonstrates that a significant proportion of primary NSCLC have low expression of AZA-induced immune genes, including PD-L1. We hypothesize that epigenetic therapy combined with blockade of immune checkpoints - in particular the PD-1/PD-L1 pathway - may augment response of NSCLC by shifting the balance between immune activation and immune inhibition, particularly in a subset of NSCLC with low expression of these pathways. Our studies define a biomarker strategy for response in a recently initiated trial to examine the potential of epigenetic therapy to sensitize patients with NSCLC to PD-1 immune checkpoint blockade
Recommended from our members
Moving the needle on colorectal cancer genetics: it takes more than two to TANGO.
Recommended from our members
Chromatin dysregulation and DNA methylation at transcription start sites associated with transcriptional repression in cancers.
Although promoter-associated CpG islands have been established as targets of DNA methylation changes in cancer, previous studies suggest that epigenetic dysregulation outside the promoter region may be more closely associated with transcriptional changes. Here we examine DNA methylation, chromatin marks, and transcriptional alterations to define the relationship between transcriptional modulation and spatial changes in chromatin structure. Using human papillomavirus-related oropharyngeal carcinoma as a model, we show aberrant enrichment of repressive H3K9me3 at the transcriptional start site (TSS) with methylation-associated, tumor-specific gene silencing. Further analysis identifies a hypermethylated subtype which shows a functional convergence on MYC targets and association with CREBBP/EP300 mutation. The tumor-specific shift to transcriptional repression associated with DNA methylation at TSSs was confirmed in multiple tumor types. Our data may show a common underlying epigenetic dysregulation in cancer associated with broad enrichment of repressive chromatin marks and aberrant DNA hypermethylation at TSSs in combination with MYC network activation
Epigenetic modelling: DNA methylation and working towards model parameterisation
The main focus of the research in this thesis is the investigation in DNA methylation mechanisms
of epigenetics and the study of a specific database. As part of the latter work, the role of curation
is described, and a new knowledge management system, PathEpigen1 , is reported that is currently
being developed for colon cancer in the Sci-Sym centre. The database deals with genetic and epigenetic
interactions and contains considerable data on molecular events such as genetic and epigenetic events.
The data curation includes biomedical and biological information. An efficient method was devised to
extract biological information from the literature to process, manage and upgrade data. We present
a Deterministic Finite Automata (DFA) model for the DNA methylation mechanism controlled by
DNA methyltransferase (DNMT) enzymes. This thesis provides a brief introduction to epigenetics, a
survey of ongoing research on computational epigenetics and a description of the DNA methylation
database. Furthermore, it also gives an overview of DNA methylation and its importance in cancer.
The DFA models three states of methylation frequency (normal, de-novo and hypermethylated) in the
cell. It has been executed on input of random strings of size 100. Out of the strings considered, we
found that 26%, 37% and 37% correspond to normal, de-novo (cancer initiation) and hypermethylated
(cancer) states, respectively
Translational Oncogenomics and Human Cancer Interactome Networks
An overview of translational, human oncogenomics, transcriptomics and cancer interactomic networks is presented together with basic concepts and potential, new applications to Oncology and Integrative Cancer Biology. Novel translational oncogenomics research is rapidly expanding through the application of advanced technology, research findings and computational tools/models to both pharmaceutical and clinical problems. A self-contained presentation is adopted that covers both fundamental concepts and the most recent biomedical, as well as clinical, applications. Sample analyses in recent clinical studies have shown that gene expression data can be employed to distinguish between tumor types as well as to predict outcomes. Potentially important applications of such results are individualized human cancer therapies or, in general, ‘personalized medicine’. Several cancer detection techniques are currently under development both in the direction of improved detection sensitivity and increased time resolution of cellular events, with the limits of single molecule detection and picosecond time resolution already reached. The urgency for the complete mapping of a human cancer interactome with the help of such novel, high-efficiency / low-cost and ultra-sensitive techniques is also pointed out
Convergence of Mutation and Epigenetic Alterations Identifies Common Genes in Cancer That Predict for Poor Prognosis
Stephen Baylin and colleagues show that a combined genetic and epigenetic analysis of breast and colon cancers identifies a number of clinically significant genes targeted by multiple modes of inactivation
Not only P-glycoprotein: amplification of the ABCB1-containing chromosome region 7q21 confers multidrug resistance upon cancer cells by coordinated overexpression of an assortment of resistance-related proteins
The development of drug resistance continues to be a dominant hindrance toward curative cancer treatment.
Overexpression of a wide-spectrum of ATP-dependent efflux pumps, and in particular of ABCB1 (P-glycoprotein
or MDR1) is a well-known resistance mechanism for a plethora of cancer chemotherapeutics including for example
taxenes, anthracyclines, Vinca alkaloids, and epipodopyllotoxins, demonstrated by a large array of published
papers, both in tumor cell lines and in a variety of tumors, including various solid tumors and hematological
malignancies. Upon repeated or even single dose treatment of cultured tumor cells or tumors in vivo with
anti-tumor agents such as paclitaxel and doxorubicin, increased ABCB1 copy number has been demonstrated,
resulting from chromosomal amplification events at 7q11.2-21 locus, leading to marked P-glycoprotein overexpression,
and multidrug resistance (MDR). Clearly however, additional mechanisms such as single nucleotide
polymorphisms (SNPs) and epigenetic modifications have shown a role in the overexpression of ABCB1 and of
other MDR efflux pumps. However, notwithstanding the design of 4 generations of ABCB1 inhibitors and the
wealth of information on the biochemistry and substrate specificity of ABC transporters, translation of this vast
knowledge from the bench to the bedside has proven to be unexpectedly difficult.
Many studies show that upon repeated treatment schedules of cell cultures or tumors with taxenes and anthracyclines
as well as other chemotherapeutic drugs, amplification, and/or overexpression of a series of genes
genomically surrounding the ABCB1 locus, is observed. Consequently, altered levels of other proteins may
contribute to the establishment of the MDR phenotype, and lead to poor clinical outcome. Thus, the genes
contained in this ABCB1 amplicon including ABCB4, SRI, DBF4, TMEM243, and RUNDC3B are overexpressed in
many cancers, and especially in MDR tumors, while TP53TG1 and DMTF1 are bona fide tumor suppressors. This
review describes the role of these genes in cancer and especially in the acquisition of MDR, elucidates possible
connections in transcriptional regulation (co-amplification/repression) of genes belonging to the same ABCB1
amplicon region, and delineates their novel emerging contributions to tumor biology and possible strategies to
overcome cancer MDR
- …